First-in-human single agent study of SAR442257 in RRMM and RR-NHL

Trial Identifier: TED16364
Sponsor: Sanofi
Start Date: July 2020
Primary Completion Date: March 2024
Study Completion Date: May 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CZECHIA Brno, CZECHIA, 62500
CZECHIA Ostrava - Poruba, CZECHIA, 70852
CZECHIA Praha 2, CZECHIA, 12808
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 06351
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 03080
NORWAY Oslo, NORWAY, 0440
NORWAY Oslo, NORWAY, 0450
SPAIN, Cantabria Santander, Cantabria, SPAIN, 39008
SPAIN, Catalunya [Cataluña] Badalona, Catalunya [Cataluña], SPAIN, 08916
SPAIN, Madrid Madrid, SPAIN, 28041
SPAIN, Madrid, Comunidad de Madrid, Madrid, Comunidad de, SPAIN, 28027
SPAIN, Navarra Pamplona, Navarra, SPAIN, 31008
SPAIN, Valencia Valencia, SPAIN, 46026
UNITED STATES, California Duarte, California, UNITED STATES, 91010
UNITED STATES, Florida Miami, Florida, UNITED STATES, 33136
UNITED STATES, Minnesota Rochester, Minnesota, UNITED STATES, 55905